The NRC located in Chengdu’s Bio-Technology Park will focus on process and method development of technically challenging specialty injectable pharmaceuticals.
The center, which is staffed with an international team of experienced research scientists, will initially focus on developing both liquid and lypholization products for Sagent China Pharmaceuticals (SCP), Sagent’s FDA-inspected manufacturing facility, also located in Chengdu.
Sagent CEO and chairman of the board Jeffrey Yordon said building a first class development center in support of the company’s manufacturing capabilities is a natural next step in its strategic evolution.
"The NRC is equipped with state-of-the-art equipment and staffed with a team of global experts in specialty injectable development," Yordon said.
"We are proud of the progress of our team in China and pleased to provide increased support for the rapid development of additional products to be manufactured at SCP."
The company is mainly focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectables.